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Intratumoral Lymphatic Vessel Involvement is an Invasive
Indicator of Completely Resected Pathologic Stage I
Non-small Cell Lung Cancer
Masahiko Harada, MD, PhD, Tai Hato, MD, and Hirotoshi Horio, MD, PhD
Introduction: Therapeutic strategies remain controversial for the
completely resected stage I non-small cell lung cancer patients with
worse long-term survival. Comprehensive patient selection for ad-
juvant chemotherapy should be based on proven risk factors.
Methods: The records of 610 patients with pathologic stage I
complete pulmonary resection were retrospectively reviewed. Sur-
vival was analyzed by the Kaplan-Meier method, log-rank test, and
Cox proportional hazards analysis.
Results: Overall 5-year survival rate was 75.1%. Univariate analysis
for all patients revealed eight significant prognostic factors: age (p
0.0001); gender (p  0.0001); histopathology (p  0.0001); differ-
entiation (p  0.0001); tumor size (T factor) (p  0.0001); pleural
involvement (p  0.0007); blood vessel involvement (p  0.0001);
and lymphatic vessel involvement (p  0.0001). Multivariate anal-
ysis revealed age, tumor size, and lymphatic vessel involvement as
significant factors. Hazard ratios for death were 0.563 for age
younger than 70 years (p  0.0004), 0.629 for T1 tumor (p 
0.0126), and 0.514 for ly() (p  0.0002). Five-year survival rates
in patients with T1 without lymphatic vessel involvement, T1 with
lymphatic vessel involvement, T2 without lymphatic vessel involve-
ment, and T2 with lymphatic vessel involvement were 88.7, 69.8,
73.5, and 56.1%, respectively. Overlapping prognoses were seen
between T1 with lymphatic vessel involvement classed as stage IA
and T2 without lymphatic vessel involvement classed as stage IB
disease.
Conclusions: Our analyses indicate lymphatic vessel involvement
as an independent indicator of cancer invasiveness, surpassing the
size-dependent tumor, node, metastasis staging system in pathologic
stage I non-small cell lung cancer. Patients who would show
survival benefits from adjuvant chemotherapy might be found by
stratifying prognostic factors.
Key Words: Non-small cell lung cancer, Lymphatic vessel inva-
sion, Pathologic stage I disease, Prognostic factor, Outcome.
(J Thorac Oncol. 2011;6: 48–54)
Non-small cell lung cancer (NSCLC) patients with patho-logic stage I disease have the best chance of cure using
surgery alone. Within the stage I designation, however, some
patient characteristics may be associated with worsened long-
term survival. Overall 5-year survival rates in resected stage
IA and IB disease range from 67 to 89% and from 57 to 75%,
respectively, indicating some degree of overlap in prognosis
because of poor prognostic factors for patients with same
stage.1–6 Identifying prognostic factors that can reflect the
risk of mortality more precisely is thus important to make a
reasonable staging diagnosis and to provide beneficial thera-
peutic strategies such as adjuvant chemotherapy for stage I
NSCLC patients. Some prognostic factors, namely smoking
history, serum level of carcinoembryonic antigen, extent of
operation, tumor size, visceral pleural invasion, vessel inva-
sion, and so on, have been proposed. Vessel invasion, includ-
ing lymphatic or blood vessel involvement, has been consid-
ered as a strong independent predictor for p-stage I disease in
particular.7–13 This study attempted to clarify factors associ-
ated with poor prognosis and to assess whether vessel inva-
sion represents a valuable prognostic criterion that can be
used to subdivide patients with pN0 and pathologic stage I
NSCLC based on survival. The records of 610 patients who
underwent complete pulmonary resection in single institution
were analyzed retrospectively.
PATIENTS AND METHODS
Between January 1990 and December 2005, a total of
610 patients were given a final diagnosis of pathologic stage
I NSCLC at our institute. We retrospectively reviewed these
cases with regard to patient characteristics, tumor pathologic
findings, and follow-up status to examine prognostic factors
in patients with p-stage I NSCLC.
No subjects had received preoperative radiotherapy or
chemotherapy. Patients with multiple lung cancers were ex-
cluded. Lobectomy or pneumonectomy with systematic
lymphadenectomy was typically performed as dictated by
tumor size and location. Wedge resection or segmentectomy
were performed in cases with peripheral localized bronchi-
oloalveolar carcinoma or poor pulmonary reserve. When
performing lesser pulmonary resection, segmental or subseg-
mental nodes were pathologically evaluated by intraoperative
frozen-section examination and confirmed as negative. All
tumors were resected with no pathologic evidence of residual
tumor at the surgical margin.
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Pathologic staging was determined according to the
International Union Against Cancer TNM Classification of
Malignant Tumors, 6th edition.14 Histologic subtypes of lung
cancer were determined according to World Health Organi-
zation classifications.15 Postoperative follow-up evaluations
were performed every 3 months for the first 2 years and every
6 months thereafter at our outpatient department.
Pleural invasion and vessel involvement in the primary
lesion were evaluated by uniform hematoxylin-eosin and
Elastica van Gieson stain on all tumors. The presence of
blood or lymphatic vessel involvement was determined by
identifying specific findings at the representative section.
Blood vessels were identified by the presence of erythrocytes
in the lumen and/or an endothelial cell lining and/or the
presence of elastic tissue around larger vessels. Lymphatic
vessels were identified by exclusion; an endothelial-lined
channel was considered a lymphatic vessel if it was devoid of
erythrocytes in the lumen and contained few lymphocytes.
Vessel involvement was determined by the identification of
intravascular tumor clots, often with endothelial covering in
the lumen of the vessels. All histologic reviews were evalu-
ated by a few pathologists, and a consensus was reached.
We adopted the following 10 clinicopathologic factors
as variables for this retrospective prognostic analysis: age;
gender; location of primary tumor; histopathology; differen-
tiation; tumor size; pleural invasion (p); blood vessel involve-
ment (v); lymphatic vessel involvement (ly); and extent of
surgical resection. Informed consent for use of clinical data
was obtained preoperatively from each patient, and the Insti-
tutional Review Board of our institution approved all study
protocols.
A 2 test was used for comparison of variables. Sur-
vival was calculated from the date of surgery until the date of
either death or last follow-up. An observation was censored at
the last follow-up if the patient was alive or had died of a
cause other than NSCLC. For univariate analysis, we con-
structed survival curves using the Kaplan-Meier method and
compared survival between groups using log-rank tests. Mul-
tivariate analysis was performed by constructing a Cox pro-
portional hazards model using the significant factors identi-
fied from univariate analysis. Values of p 0.05 were
considered significant. Statistical analyses were performed
using StatView statistical software (StatView v5.5, SAS In-
stitute, Inc., Cary, NC).
RESULTS
Clinicopathologic characteristics of patients are shown
in Table 1. The study cohort included 372 men and 238
women with a mean age of 67 years (range, 27–87 years).
Underlying pathology was adenocarcinoma in 388 patients
(64%) and other histologic types in 222 patients (36%). Of
the 388 patients with adenocarcinoma, 111 had bronchioloal-
veolar carcinoma. Diagnosis of p-stage IA (T1) disease was
made in 337 patients (55%), and diagnosis of p-stage IB (T2)
was made in 273 patients (45%). Tumor 20 mm in diam-
eter, 20 to 30 mm, 30 to 50 mm, or 50 mm was
seen in 182 (30%), 155 (25%), 184 (30%), and 89 patients
(15%), respectively. A total of 212 patients (34%) had a
tumor with pathologically proven pleural invasion (p1 or p2).
Lobectomy or pneumonectomy was performed in 485 pa-
tients (80%), and lesser pulmonary resection was performed
in 125 patients (20%). Blood vessel involvement (v) was
found in 315 patients (51%), and lymphatic vessel involve-
ment (ly) was found in 225 patients (36%). Vessel invasion
rate, which indicates lymphatic or blood vessel involvement
or both, was 57% (353 patients). Both ly and v were detected
significantly more frequently in those with larger-sized tu-
mors, nonadenocarcinoma, or pleural invasion (Table 2). A
strong relationship between ly and v expression could also be
seen. Of the 111 patients (18%) with bronchioloalveolar
carcinoma, v was found in seven patients (1%) and ly was
found in nine patients (1%). Both ly and v were detected
significantly more frequently in those with larger-sized tu-
mors, especially in tumor 20 mm in diameter (Table 2).
Median postoperative follow-up was 59 months (range,
1–322 months). There were 173 deaths during the follow-up
period, and overall 5-year survival was 75.1% (p-stage IA,
83.4%; p-stage IB, 64.9%).
TABLE 1. Clinicopathologic Characteristics of Patients
(n  610)
Factors N
Age (27–87 yr)
Mean (median) 67 (68)
Gender
Male 372
Female 238
Location 1
Right 383
Left 227
Location 2
Upper lobe 356
Middle & lower lobes 254
Histopathology
Adenocarcinoma 388
Nonadenocarcinoma 222
Differentiation
Well 282
Nonwell 328
Tumor size
30 mm 337
30 mm 273
Pleural invasion
p() 212
p() 398
Blood vessel invasion
v() 315
v() 295
Lymphatic vessel invasion
ly() 225
ly() 385
Extent of surgery
Major 485
Lesser 125
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Univariate analysis among overall patients revealed
eight significant prognostic factors (p  0.05): age; gender;
histopathology; differentiation; tumor size; pleural involve-
ment; blood vessel involvement; and lymphatic vessel in-
volvement (Table 3). Overall 5-year survival was signifi-
cantly lower for patient with ly() (61.5%) compared with
ly() (83.1%, p  0.0001) and for patients with v()
(67.3%) compared with v() (82.6%, p  0.0001). Univar-
iate analysis of other additional prognostic factors included
age (younger than 70 years versus 70 years or older: 81.9
versus 65.2%; p  0.0001), gender (female versus male:
80.9 versus 71.4%; p  0.0001), histopathology (adenocar-
cinoma versus nonadenocarcinoma: 81.2 versus 64.4%; p 
0.0001), differentiation (well differentiated versus not well
differentiated: 80.7 versus 70.3%; p  0.0001), tumor size
(30 versus 30 mm: 83.4 versus 64.9%; p  0.0001), and
pleural invasion (p() versus p(): 65.2 versus 80.1%; p 
0.0007). No significant differences were seen for primary
location or extent of surgical resection.
Multivariate analysis demonstrated age, tumor size,
and lymphatic vessel involvement, but not blood vessel
involvement, as strong independent prognostic factors af-
ter adjusting for the eight factors extracted by univariate
analysis. The hazard ratio for death was 0.563 (95%
confidence interval [CI], 0.409–0.774; p  0.0004) for
age 70 years, 0.629 (95% CI, 0.437–0.905; p  0.0126)
for tumor 30 mm in diameter, and 0.514 (95% CI,
0.364–0.726; p  0.0002) for having no lymphatic vessel
involvement (Table 4).
Survival curves stratified according to both tumor size
(30 mm or 30 mm) and lymphatic vessel involvement
(ly() or ly()) are shown in Figure 1. The 5-year survival
rates in patients with T1 and ly(), T1 and ly(), T2 and
ly(), and T2 and ly() were 88.7, 69.8, 73.5, and 56.1%,
respectively. The difference in survival probability between
ly() and ly() was clinically significant in both the T1
(stage IA) group (p  0.0002) and the T2 (stage IB) group
(p  0.0006). Difference in survival probability, however,
was not significant between T1 with ly() and T2 with ly()
(p 0.5175) groups. As a result, overlapping prognoses were
seen between the T1 with ly() group classed as stage IA and
the T2 with ly() classed as stage IB. Furthermore, overall
survival was worse for the T2 with ly() group than the
61.0% for pathologic stage IIA based on a Japanese Lung
Cancer Registry study in 2005.6
TABLE 2. Relationship Between Intratumoral Vessel Invasion and Other
Clinicopathologic Factors in 610 All Cases and in 111 Cases with BAC
Factors n
Intratumoral Vessel Invasion
ly()/ly() p v()/v() p
All cases (n  610)
p-T factor
T1 337 92/245 0.0001 118/219 0.0001
T2 273 133/140 197/76
Tumor size
0 to 20 mm 182 40/142 0.0199 43/139 0.0001
20 to 30 mm 155 52/103 0.0448 75/80 0.0001
30 to 50 mm 184 82/102 0.0534 134/50 0.7738
50 mm 89 51/38 63/26
Histology
Adenocarcinoma 388 121/267 0.0002 149/239 0.0001
Others 222 104/118 166/56
Pleural invasion
p() 212 118/94 0.0001 169/43 0.0001
p() 398 107/291 146/252
Cases with BAC (n  111)
p-T factor
T1 100 6/94 0.0442 3/97 0.0016
T2 11 3/8 4/7
Tumor size
0 to 20 mm 78 5/73 0.9999 3/75 0.9999
20 to 30 mm 22 1/21 0.0475 0/22 0.0026
30 to 50 mm 8 3/5 0.9999 4/4 0.2264
50 mm 3 0/3 0/3
Pleural invasion
p() 5 1/4 0.3501 2/3 0.0104
p() 106 8/98 5/101
BAC, bronchioloalveolar carcinoma.
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DISCUSSION
The objective of this study was to identify indepen-
dent prognostic factors and determine whether vessel in-
vasion represents a valuable prognostic criterion that can
be used to subdivide patients with pathologic stage I
NSCLC. The principle findings were that lymphatic vessel
involvement is an independent indicator of cancer inva-
siveness, surpassing tumor size in pathologic stage I
NSCLC. The clinical relevance of this study is strength-
ened by the relatively large sample drawn from a recent
time period reflective of current trends.
Several clinicopathologic prognostic factors for stage I
NSCLC have been identified. These factors include blood
vessel involvement,16,17 lymphatic vessel involvement, de-
gree of nuclear atypia,16 mitotic index,16,17 degree of histo-
logic differentiation,17,18 serum carcinoembryonic antigen
level,13 and other histologic parameters associated with stro-
mal invasion, such as scar grade.19,20 With regard to vessel
invasion, both lymphatic and blood vessel involvement have
long been considered as useful prognostic factors.16,21 Some
studies have reported that only lymphatic vessel involvement,
and not blood vessel involvement, was significantly related to
decreased survival because of the high frequency of blood
vessel invasion but the lower incidence of metastasis.21,22
Other groups have indicated that cells from small cancers
metastasize preferentially via the blood vessels.9,23,24 In our
study, both lymphatic and blood vessel involvement were
factors associated with poor prognosis according to univariate
analysis. Overall survival was significantly lower for patients
with ly() (61.5%) compared with that seen in ly() (83.1%,
p  0.0001) and for patients with v() (67.3%) compared
with that seen in v() (82.6%, p  0.0001). With multivar-
iate analysis, however, only lymphatic vessel involvement,
and not blood vessel involvement, was identified as an inde-
pendent prognostic factor. Together with lymphatic vessel
involvement, age and tumor size were also extracted as
independent prognostic factors. The hazard ratio with no
lymphatic vessel involvement of 0.514 (p  0.0002) was
smaller than those for other independent prognostic factors
(tumor 30 mm, 0.629 [p  0.0126]; age 70 years, 0.563
[p  0.0004]). These findings suggest that lymphatic vessel
involvement in pathologic stage I NSCLC patients has a
stronger invasive tumor biology than other factors extracted
by univariate analysis (e.g., blood vessel involvement [p 
0.0001], age [p  0.0001], gender [p  0.0001], histopathol-
ogy [p  0.0001], differentiation [p  0.0001], tumor size
[p 0.0001], or pleural invasion [p 0.0007]). The invasive
nature of tumors with lymphatic vessel involvement must be
highly contributory to poor prognosis. Shimizu et al.25 re-
ported that age, gender, pleural invasion, lymphatic vessel
involvement, and blood vessel involvement were all indepen-
dent prognostic factors in pathologic stage I NSCLC, but we
were unable to confirm the independence of these factors in
our population, perhaps because of some confounding due to
the strong correlation between lymphatic vessel involvement
and other factors associated with poor prognosis. In fact, we
found a significant and positive association between positive
lymphatic vessel involvement and tumor size, pleural inva-
sion, or histology (Table 2). Although there is some possi-
bility that each factor is valuable, further investigation is
needed before these prognostic factors can be adapted to the
staging system.
One important issue is the method of confirming vessel
involvement. This study used hematoxylin-eosin and Elastica
TABLE 3. Univariate Analysis by the Kaplan-Meier Method
Variable 5-yr Survival (%) p
Age 0.0001
70 yr 81.9
70 yr 65.2
Gender 0.0001
Female 80.9
Male 71.4
Histology 0.0001
Adenocarcinoma 81.2
Others 64.4
Differentiation 0.0001
Well differentiated 80.7
Others 70.3
Tumor size 0.0001
30 mm 83.4
30 mm 64.9
Pleural invasion 0.0007
p() 80.1
p() 65.2
Blood vessel invasion 0.0001
v() 83.1
v() 61.5
Lymphatic vessel invasion 0.0001
ly() 82.6
ly() 67.3
TABLE 4. Prognostic Factors Based on a Multivariate
Analysis by Cox Proportional Hazards Model
Variable Hazard Ratio 95% CI p
Age
70 yr vs. 70 yr 0.563 0.409–0.774 0.0004
Gender
Male vs. female 0.730 0.501–1.062 0.0999
Histology
Adenocarcinoma vs. others 1.280 0.885–1.852 0.1905
Differentiation
Well vs. others 1.175 0.797–1.731 0.4154
Tumor size
30 mm vs. 30 mm 0.629 0.437–0.905 0.0126
Pleural invasion
p() vs. p() 0.860 0.605–1.222 0.4000
Blood vessel invasion
v() vs. v() 1.001 0.664–1.509 0.9975
Lymphatic vessel invasion
ly() vs. ly() 0.514 0.364–0.726 0.0002
CI, confidence interval.
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van Gieson stain to confirm intratumoral vessel invasion.
These staining methods offer reliable detection of tumor cells
in vessels, although the ability to differentiate between lym-
phatic vessel involvement and blood vessel involvement is
limited. The value of elastic staining can be inferred by
referring to past studies in which vessel involvement was
evaluated. Detection rates of lymphatic vessel involvement
and blood vessel involvement in p-stage I without the elastic
staining method were 0 to 3% and 11 to 16%, respectively.8,9
In contrast, detection rates for lymphatic vessel involvement
and blood vessel involvement with the elastic staining
method were 40 to 52% and 27 to 56%, respectively.7,10,21
Generally, the reported detection rate of intratumoral vessel
invasion was higher in studies using elastic staining to eval-
uate intratumoral vessel invasion. Although this indicates that
elastic staining enables pathologists to more precisely detect
intratumoral vessel invasion, the consistency of detection is
still not good enough. How to consistently diagnose the blood
or lymphatic vessel involvement is a crucial point when
introducing these factors to tumor, node, metastasis (TNM)
staging and standardizing the adjuvant therapy. Immunohis-
tochemistry may be useful for the identification of lymphatic
vessel involvement. Recently, it has been shown that a
monoclonal antibody D2-40 specifically recognizes podopla-
nin26 and that both antibodies against D2-40 and podoplanin
can be regarded as reference standards for the identification
of lymphatic vessels in various human cancers including
NSCLC.27,28 Both antipodoplanin and D2-40 antibodies have
a sensitivity and specificity for lymphatic endothelium of
more than 95%.29 Therefore, lymphatic vessel involvement is
able to be defined if at least one tumor cell is visible within
D2-40-positive lining spaces. Further investigations will be
needed to address this issue.
Tumor diameter in the maximum dimension is a valuable
and readily available prognostic factor based on gross anatomic
findings. Clinicians, however, sometimes encounter patients
who show a worse prognosis than expected based on tumor size,
as well as patients showing a better prognosis. Although this
study has shown the significance of tumor size (e.g.,30 versus
30 mm) for prognosis in resected p-stage I NSCLC by mul-
tivariate analysis, tumor size (e.g.,20 versus20 to30 mm)
was not an independent predictor of survival by subgroup
analysis in resected p-stage IA NSCLC (data not shown). One
possible reason for the discrepancy between size classification
and prognosis might be the limited value of evaluating invasive-
ness by tumor size alone. For example, bronchioloalveolar
carcinoma (BAC) is a noninvasive form of adenocarcinoma that
is often included in the smaller T category, and patients have
been known to show good clinical outcomes after surgical
resection of a BAC component.30 As BAC involves neither
stroma nor vessels, differences in the proportion of BAC can
cause size-independent differences in prognosis among patients
with adenocarcinoma. In this study, the histologic category of
adenocarcinoma might have included BAC, and prognostic
significance was not demonstrated independently. Almost a third
of adenocarcinoma was BAC, which made up 18% of the
population studied. Regarding characteristics of BAC studied, 6
and 8% of all BAC showed v and ly, respectively, besides 31%
of all BAC was 20 mm in size. Therefore, some degree of
BAC with invasive nature, not behaving carcinoma in situ,
might have included in this population. When the entire statis-
tical analysis was repeated after excluding all BAC, so that we
would minimize the influence of favorable BAC proportion,
general trends of the results were entirely same (Appendix). On
the other hand, lymphatic vessel involvement may act as a
prognostic factor in patients for whom prognosis cannot be
precisely predicted on the basis of tumor size. This study has
demonstrated that 37 and 35% of20 mm tumors except BAC
revealed v and ly, respectively, indicating that the proportion of
small-sized tumor with aggressive nature may be relatively high
in this series (data not shown). Subgroup analysis in resected
p-stage IA NSCLC showed that lymphatic vessel involvement
alone, and not tumor size, was an independent prognostic factor
(data not shown). This suggests that lymphatic vessel involve-
ment may be a stronger prognostic factor than tumor size,
particularly in the p-stage IA. We think that lymphatic vessel
involvement status directly indicates microscopic tumor pro-
gression. Prognostic prediction using lymphatic vessel involve-
FIGURE 1. Survival curves strati-
fied according to p-T factor and
lymphatic vessel involvement.
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ment is applicable to any tumor, regardless of histology, and
complements the present size-dependent TNM staging system.
The purpose of the staging system is to describe the
anatomic extent of disease and to group staged subsets by
survival. However, as with other solid tumor staging systems,
this system does not take into account tumor biology. It was
understood at the inception of this system that revision of the
staging system would probably be appropriate as additional data
about influences on survival became available. Therefore, when
adopting new factors as specific descriptors in the staging sys-
tem, we must be aware of correlations between factors, which
factors are independent and which factors represent the most
suitable candidates. Although the pathologic TNM staging sys-
tem has been considered to have an impact on survival in
NSCLC, problems such as overlapping prognosis for patients
with different tumor stages and heterogeneous prognosis for
patients with the same tumor stage have been noted.2,6 In this
study, survival curves stratified according to both tumor size
(30 or 30 mm) and lymphatic vessel involvement (ly() or
ly()) revealed overlapping prognoses between the 30 mm
with ly() group classed as stage IA and the 30 mm with
ly() group classed as stage IB disease. This phenomenon
similarly occurred even when survival analysis was repeated
after excluding favorable BACs. The 5-year survival rates in
patients with T1 and ly(), T1 and ly(), T2 and ly(), and T2
and ly() were 84.1, 67.6, 73.3, and 55.7%, respectively. As the
proposed size classification could not predict tumor invasive-
ness, we think that lymphatic vessel involvement complements
the staging system. Our data support upstaging of patients with
lymphatic vessel involvement from stage IA to stage IB and
from stage IB to stage IIA, allowing identification of patients
with stage I NSCLC who have poor prognosis and correcting
overlapping prognosis in the current staging system.
Overlapping prognosis needs to be resolved to provide
reasonable adjuvant treatment or follow-up care for patients with
differing risk of relapse or death due to tumor. The standard of
care for resected stage II to IIIA NSCLC now includes adjuvant
chemotherapy based on the results of three phase III studies
using cisplatin-based regimens.31–33 However, the role of adju-
vant chemotherapy for stage I disease remains controversial.
Updated results from the Cancer and Leukemia Group B 9633
trial, the only trial to focus exclusively on patients with stage IB
disease, no longer show a significant survival benefit from
adjuvant chemotherapy in this population.34 Patients who would
gain survival benefits might be found by stratification according
to lymphatic vessel involvement.
CONCLUSIONS
Our analyses indicated lymphatic vessel involvement as
an independent indicator of cancer invasiveness, surpassing
the size-dependent TNM staging system in pathologic stage I
NSCLC. Upstaging of patients with lymphatic vessel in-
volvement from stage IA to stage IB and from stage IB to
stage IIA would allow the identification of patients with stage
I NSCLC who have poor prognosis and would correct over-
lapping prognosis in the current staging system. Patients who
would gain survival benefits from adjuvant chemotherapy
might be found by stratifying according to prognostic factors.
APPENDIX
TABLE A1. Statistical Analysis Repeated After Excluding
BACs (n  499): Univariate Analysis by the Kaplan-Meier
Method
Variable 5-yr Survival (%) p
Age 0.0002
70 yr 78.5
70 yr 60.9
Gender 0.0102
Female 76.0
Male 69.2
Histology 0.0008
Adenocarcinoma 77.0
Others 64.3
Differentiation 0.0462
Well differentiated 73.3
Others 70.3
Tumor size 0.0013
30 mm 78.1
30 mm 64.4
Pleural invasion 0.0335
p() 75.7
p() 64.6
Blood vessel invasion 0.0028
v() 77.4
v() 66.9
Lymphatic vessel invasion 0.0001
ly() 79.7
ly() 60.2
TABLE A2. Statistical Analysis Repeated After Excluding
BACs (n  499): Prognostic Factors Based on a Multivariate
Analysis by Cox Proportional Hazards Model
Variable Hazard Ratio 95% CI p
Age
70 yr vs. 70 yr 0.575 0.417–0.794 0.0008
Gender
Male vs. female 0.798 0.547–1.162 0.2391
Histology
Adenocarcinoma vs. others 1.285 0.890–1.857 0.1810
Differentiation
Well vs. others 1.065 0.728–1.559 0.7448
Tumor size
30 mm vs. 30 mm 0.692 0.483–0.992 0.0448
Pleural invasion
p() vs. p() 0.885 0.623–1.255 0.4919
Blood vessel invasion
v() vs. v () 1.068 0.715–1.596 0.7465
Lymphatic vessel invasion
ly() vs. ly() 0.533 0.379–0.751 0.0003
BAC, bronchioloalveolar carcinoma; CI, confidence interval.
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